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Abstract
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Mast  cells  (MCs)  are  immune  cells  that  release  preformed  mediators  from  granules
when activated by e.g. bacteria, viruses  and allergens.  Among the granule  components
are proteoglycans, histamine and proteases (chymase,  tryptase  and  carboxypeptidase
A).  The  proteases  are  bound  to  serglycin  proteoglycans  in  the  granules,  and  some
remain attached to the proteoglycans  after expulsion  from the secretory  granules.  The
importance of the interaction between proteases and proteoglycans is exemplified by
MCs  lacking  an  enzyme  essential  for  heparin  biosynthesis,  N-deactylase/N-
sulfotransferase-2 (NDST-2). Mice with this deficit display impaired storage of  many
MC granule components, e.g. proteases and histamine.
We could show that polycationic compounds inhibited chymase (mMCP-4/rMCP-1)  by
disrupting  its  interaction  with  heparin.  Furthermore,  these  polycations  inhibited
human  tryptase  (recombinant  βI-tryptase)  and  made  the  otherwise  resilient  enzyme
susceptible to macromolecular  inhibitors.  Our findings  may be of therapeutic  interest
when treating pathologies associated with these enzymes.
Mast cells may take part in regulation of blood pressure  and  angiogenesis,  and  this
could occur through metabolism of the peptide angiotensin I (AngI).  We confirmed  the
MC  involvement  in  AngI  processing  using  the  NDST-2  deficient  mice.  We
subsequently elucidated that the responsible proteases were  chymase  (mMCP-4) and
carboxypeptidase A (CPA), and that  they  acted  in  concert  on  AngI, producing  both
blood pressure elevating peptides and blood pressure reducing peptides.
Mast cells are implicated  in connective  tissue  regulation,  and a suggested  pathway is
through  activation  of  matrix  degrading  enzymes,  e.g.  the  matrix  metalloproteases
(MMPs).  We  could  show  that  activation  of  proMMP-9  is  dependent  on  MCs,  and
especially the chymase mMCP-4, as shown by impaired  processing  of  proMMP-9  in
peritoneal cell cultures from mice lacking NDST-2 or mMCP-4. Investigation of tissues
from mMCP-4
-/- revealed increased  deposits  of  extracellular  matrix  components  and
reduced levels MMP-9. Additionally, we could show that  proMMP-2  processing  was
completely  abolished  in  peritoneal  cell  cultures  from  mice  lacking  serglycin.
Furthermore, we showed that the formation of MMP-2 was abrogated  in the presence of
serine protease inhibitors and when cell cultures were depleted of MCs. The latter study
reveals a novel  pathway  for  proMMP-2  processing,  which  could  be  of  relevance  in
connection with MMP2-associated pathological conditions such as cancer.
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proteoglycan, allergy, arthritis, cancer
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To my loving family
“If  I  have  seen  further  it  is  by  standing  on  the
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Introduction
The immune system
Our environment contains matters essential for our existence, such as air, water
and food. These components also hold  organisms, which are possibly  harmful,
e.g. viruses, bacteria and parasites. In order to keep these pathogens out, we have
the natural barriers of skin and mucosal surfaces.  Once the  foreign organisms
penetrate these barriers, their presence activates cells of the immune system.
The immune system comprises two  components,  the  innate  response and  the
acquired/adaptive response. The innate part of the immune system is common to
all humans, and enables us to mount a defense toward disease even on  the first
encounter with the pathogen. The acquired immune system  produces pathogen
strain-specific antibodies and the specificity increases upon repeated exposure to
the pathogen.
The immune system comprises several different cell types, of which the majority
belong to the leukocyte family. One group of leukocytes  is  the  lymphocytes,
which consists of T-cells and B-cells. The B-cells produce antibodies, whereas the
T-cells, among other things, govern the type of antibody that the B-cell produces.
The second leukocyte group is  the  phagocytic cells  (mononuclear phagocytes,
polymorphonuclear neutrophils and eosinophils), which can utilize the antibodies
produced by B-cells to bind, engulf and neutralize pathogens. The phagocytic cells
can recognize pathogens by other means than antibodies, and present pathogen
specific antigens to  T-cells, thereby influencing the acquired immune response.
Additionally, there  are mast  cells  (MCs),  basophils  and  platelets,  commonly
referred to as auxiliary cells. Their purpose is e.g. to induce  inflammation  to
attract leukocytes to the site of infection, but the release of different mediators also
affects the development of the immune reaction.
Mast cells
MCs are highly granulated cells situated in the interface between the interior and
the exterior environment, e.g. the skin, airways and gastro-intestinal tract. They
were given their name by Paul Ehrlich in 1877 who, using aniline dyes, described
a cell type that looked “well-fed” due to granules filling the cytoplasm. His more
descriptive name of these cells was “granular cells of the connective tissue”. These
cells have gained increased attention in  recent  decades as  evidence of  their
involvement in several physiological and pathological conditions accumulates.
The MC exerts its function partly by components stored  in  the  granules that
Ehrlich described, but also through substances produced in response to activation.
The immediate surroundings influence the composition and response of the MC.10
Mast cell heterogeneity
Although  the  MCs  have  many  common  features,  regardless of  species  and
distribution,  they  are  not  a  homogenous  population.  Hardy  and  Westbrook
described tissue-dependent morphological differences in rat MCs  as long  ago as
1895, but it was not until 1966 that these findings were further  substantiated
(Enerbäck, 1966). MCs arise from bone-marrow and differentiate into  circulating
CD34
+/CD13
+/c-kit
+/CD14
- progenitors in humans (Kirshenbaum et al., 1999),
whereas the mouse MC progenitor is characterized as  c-kit
hi/Thy-1
lo  and  lacks
FcεRI (Rodewald et al., 1996). The progenitors migrate into  tissues,  where the
microenvironmental influence gives rise to MC subtypes. A broad division  of
MCs in the mouse is  connective tissue type mast  cells (CTMCs) and mucosal
type mast cells (MMCs), a classification based on tissue location, proteases and
proteoglycan repertoire. The CTMCs locate to  the  skin  and  peritoneal cavity,
express chymase, tryptase, CPA (Carboxypeptidase A), heparin proteoglycan and
high levels of histamine. MCs situated in the lamina propria of the intestine and
airways display an MMC phenotype, with expression of chymase,  chondroitin
sulfate proteoglycan (CSPG) and low levels of histamine.
Human MCs are also divided into two groups; MCT, expressing tryptase, and
MCTC, expressing chymase, cathepsin G and CPA in addition to tryptase.  Further
characterization of these subsets shows that they can be classified according to the
cytokines and eiocosanoid mediators that they produce;  MCTCs  preferentially
produce IL-4, IL-13 and PGD2, whereas MCTs preferentially synthesize IL-5, IL-6
and LTC4 (Macglashan et al., 1982;  Lawrence, I. D. et al., 1987;   Bradding et
al., 1995;   Anderson et al., 2001). The MCT  subset is  situated in  the lamina
propria of the airways and gastrointestinal tract, while the MCTC subtype is found
in the subepithelium and dermis.
Table 1: Heterogeneity of MCs in man and mouse11
Mast cell activation
The MCs are highly versatile in their response mechanisms as they are able to
respond to many different stimuli.  The response is  governed by  the manner in
which they become activated, i.e. through the specific type of receptors that are
engaged. On MCs, the FcεRI and its ligand, IgE, are among the most extensively
studied means of activation. There are several non-IgE mediated ways of activating
MCs  and  in  the  following  paragraphs,  IgE-dependent  and  IgE-independent
activation mechanisms will be discussed.
IgE-dependent mast cell activation
In order to accomplish  MC  activation  through  its  IgE-receptors, interaction
between IgE-molecules bound to  the receptors has to  occur in  a process called
cross-linking where an antigen interacts with at least two IgE-molecules. The MC
expresses and presents the high affinity receptor for IgE, FcεRI, which consists of
three subunits; FcεRIα, FcεRIβ and FcεRIγ. The receptor is  assembled in  its
tetrameric structure (αβγ2) in the endoplasmic reticulum before transfer into  the
Golgi  network  and  transport  to  the  plasma  membrane.  In  this  tetramer,  the
subunits have different tasks. The α-chain is responsible for binding the Fc part of
IgE (Hakimi et al., 1990;   Blank,  Ra  &  Kinet, 1991;    Lin,  S. et al., 1996),
thereby tethering IgE to the cell surface. The  β-chain amplifies  the  signal  by
interaction with the kinase, Lyn, which phosphorylates the β- and γ-chains upon
receptor activation (Jouvin et al., 1994;  Lin, S. et al., 1996). The γ-chains, once
phosphorylated by Lyn, are responsible for conveying the signal  into  the  cell
through activation of Syk (Jouvin et al., 1994;  Shiue, Zoller & Brugge, 1995).
An alternative to Lyn-mediated activation is through a Fyn-dependent pathway
(Parravicini et al., 2002), but whether these pathways display any cross-talk is not
yet elucidated.
The tetrameric assembly of FcεRI is essential for presentation on the cell surface
in rodents, whereas in humans there is an isoform of FcεRI that lacks the β-chain.
The distribution of FcεRI is also not limited to MCs and basophils in humans,
but is also found on monocytes, dendritic cells and eosinophils, although only in
its trimeric configuration (αγ2) (Maurer, D. et al., 1994;  Maurer, D. et al., 1996;
Sihra et al., 1997). An interesting finding is that binding of monomeric IgE, i.e.
non-crosslinked, to FcεRI on MCs results in an increased number of FcεRI at the
cell surface (Furuichi, Rivera & Isersky, 1985;  Yamaguchi et al., 1997), partly
through protection against  receptor break-down and  partly  through  increased
receptor translation. The interaction between receptor and its ligand also primes the
effector function of the MC by upregulating synthesis of mediators such as
cytokines (Yamaguchi et al., 1997;  Yano et al., 1997).12
Figure 1: Graphic representation of different mast cell activation mechanisms.
IgG-regulated activation
There are at least three sub-types of IgG-receptors present on  MCs  under certain
conditions;  the  activating  receptors,  FcγRI  and  FcγRIII  and  the  inhibiting
receptor, FcγRII. The high affinity receptor FcγRI, consisting of one IgG-binding
α-chain and the homodimer of γ-chains with ITAM-motifs found in the FcεRI-
receptor, is found on human MCs under the influence of interferon-γ (Okayama,
Y., Kirshenbaum & Metcalfe, 2000). It seems to preferentially interact with IgG1
rather  than  IgG2,  IgG3  or  IgG4,  and  engagement  leads  to  degranulation,
prostaglandin  synthesis  and  cytokine  production  (Woolhiser,  Brockow  &
Metcalfe, 2004).
Although FcεRI and FcγRI share γ-subunits (Tkaczyk et al., 2004), and it is
expected that  they  would  have  similar  activation  pathways  in  MCs,  some
differences have been described.  Following FcγRI activation, the mRNA and/or
protein levels for IL-1β, IL-5 and TNF-α are higher compared to FcεRI activation
although degranulation, arachidonic acid  metabolite  release  and  number  of
cytokines synthesized was similar (Okayama, Yoshimichi, Hagaman & Metcalfe,
2001;   Woolhiser et al.,  2001).  The  finding  that  MCs  express  FcγRI  and
degranulate upon IgG cross-linking implicates them  in  TH1  types  of  immune
responses.13
Human and rodent MCs appear to differ in the expression of IgG-receptors, as
the FcγRI has yet to be detected on murine MCs. In the mouse, the low affinity
IgG receptor, FcγRIII, is found on MCs of the connective tissue type, but not on
mucosal type MCs (Katz & Lobell, 1995). Its structure of one α-chain and a
homodimer  of  γ-subunits is analogous to that of the  FcγRI  receptor and  the
FcγRIII is responsible for IgG-mediated degranulation of MCs in the absence of
FcγRI (Katz et al., 1992).
The third IgG-receptor subtype,  FcγRII,  is  involved  in  restricting the  MC
response. FcγRII consists of a single α-chain with an intracellular tail containing
an ITIM-motif, which upon phosphorylation activates phosphatases that neutralize
degranulation-inducing  mediators  like  inositol-3-phosphate  (Ono,  M. et al.,
1996), thereby modulating the strength of the MC response. The FcγRII receptor
not only negatively regulates IgG-mediated MC  activation,  but  it  also  affects
activation  accomplished  through  IgE  cross-linking  by  down-regulating  the
secretory response (Daeron & Vivier, 1999;   Kepley et al., 2000),  making  it
important in both TH1 and TH2 reactions. A fourth receptor subtype, belonging to
the immunoglobulin superfamily, is the gp49 family. This  subgroup, which is
preferentially expressed on MCs  and  mononuclear macrophages, also  contains
ITIM motifs, suggesting a function similar to FcγRII (Katz et al., 1996).
Complement mediated activation
Activation of MCs through interaction with C3a and C5a, components of  the
complement system, has long been known (Johnson, Hugli  &  Muller-Eberhard,
1975).  In  rodents,  it  appears  to  be  only  CTMCs  that  can  respond  to  these
mediators since MMCs do not express the appropriate receptors (Mousli et al.,
1994). Human MCs also have differential expression of complement receptors.
The receptor for C5a is  found on  human skin  MCs,  but  they do  not  seem to
present any receptors for C3-derived components  during  base-line  conditions
(Fureder et al., 1995). In contrast, human lung MCs do not respond any of these
stimuli. However, both receptors can be  detected  in  patients  with  systemic
mastocytosis (Nunez-Lopez et al., 2003).
Toll-like receptors
In its defensive role against bacteria, the MC  is  able to  recognize parts of the
bacterial cell such as the gram-negative cell wall component, lipopolysaccharide
(LPS). This recognition is attributed to the Toll-like receptors (TLRs), which is a
family comprising eleven members identified so far (Rock et al., 1998;  Takeuchi
et al., 1999;  Du et al., 2000;  Chuang & Ulevitch, 2001;  Zhang et al., 2004).
The common features of this family are a leucine-rich extracellular domain and a
Toll/IL-1  receptor-domain  in  their  intracellular  region  (Medzhitov,  Preston-
Hurlburt & Janeway, 1997). MCs express TLR-2, 3, 4, 6, 7,  8  and 9  (Takeda,
Kaisho & Akira, 2003;   Matsushima et al., 2004), as determined on cultured
rodent MCs. Deletion of the gene coding for TLR-4 showed that this receptor is
responsible for LPS-recognition, and hence recognition of gram-negative bacteria
(Hoshino et al., 1999). Peptidoglycan, a constituent of gram-positive  bacteria,14
elicits a response through binding to TLR-2 (Supajatura et al., 2002), as does a
variety of pathogen-derived lipoproteins as well as the fungal element, zymosan
(Takeda, Kaisho & Akira, 2003). In contrast to  TLR-4, which is  functional by
itself, TLR-2 seems to be dependent on TLR-1 and -6 for correct recognition of
microbial components (Ozinsky et al., 2000). In the defense against viruses, the
MC produces TLR-3 which recognizes dsRNA (Kulka et al., 2004), and gives rise
to type I IFN transcripts of IFNα and β. The interaction between the pathogen-
derived components and TLRs on  MCs  causes an  activation,  which  leads  to
expression and release of cytokines, leukotrienes and prostaglandins (Marshall,
King & Mccurdy, 2003;  Okumura, S. et al., 2003;  Varadaradjalou et al., 2003).
In contrast to IgE-mediated activation, TLR-induced MC activation usually does
not lead to degranulation, but to release of mediators in a process referred to  as
piece-meal release.
Miscellaneous mast cell activators
In addition to the ways of activating MCs already listed, other mechanisms may
apply. Peptides such as substance P, neurotensin and vasoactive intestinal peptide
(VIP), which are released by neurons, are able to provoke adjacent MCs (Bauer &
Razin, 2000). Certain cytokines and chemokines are also able to elicit a response,
which has been shown for IL-1, IL-3, SCF,  macrophage inflammatory protein-1α
(MIP-1α) and monocyte chemoattractant peptide-1 (MCP-1) (Alam et al., 1994;
Mekori & Metcalfe, 2000). Furthermore, cell-to-cell interactions can activate MCs;
activated T-cells can induce degranulation and cytokine production through the
interaction between intracellular adhesion molecule-1 (ICAM-1) and leukocyte
function-associated antigen-1 (LFA-1) (Bhattacharyya et al., 1998;  Inamura et al.,
1998). Substances that directly activate MCs include opiates, calcium ionophores,
compound 48/80, endothelin and adenosine (Metcalfe, Baram & Mekori, 1997). In
addition  to  compound  induced  activation,  there  is  also  activation  due  to
physiological stress such as changes in osmolarity and pressure.
Mast cell mediators
MCs express a multitude of mediators. Some are stored in secretory granules and
can be released upon stimulation (histamine, neutral proteases, proteoglycans and
preformed cytokines) and others that are expressed only upon MC activation.
De novo-synthesized mediators
Prostaglandins and Leukotrienes
Prostaglandins (PGs) and leukotrienes (LTs) are lipid  mediators derived from a
common precursor, arachidonic acid, which is released from the plasma membrane
by the action of cytosolic phospholipase A2 (cPLA2) (Uozumi et al., 1997).
LTs encompass the unstable LTA4, LTB4 and the cysteinyl-leukotrines (cys-LTs)
LTC4, LTD4 and LTE4. Neutrophils preferentially form LTB4 (Evans, Dupuis &
Ford-Hutchinson, 1985), whereas MCs, basophils and eosinophils predominantly
form LTC4 through conjugation of glutathione and LTA4 by LTC4 synthase (Lam
et al., 1994). LTC4 is further processed extracellularly into LTD4  (Carter et al.,
1998), which in turn is metabolized into LTE4 (Lee, C. W. et al., 1983).15
To exert their effect, cys-LTs interact with two receptors, CysLT1 and CysLT2.
These receptors have somewhat overlapping tissue-distribution, and both are found
on human MCs. Their affinity towards cysLTs differ; CysLT1 has the highest
affinity to LTD4 and bind LTC4 and LTE4 with less affinity, CysLT2 binds LTC4
and LTD4 with equal affinity but show weaker interaction with LTE4 (Kanaoka &
Boyce, 2004). The physiological effects of cysLTs with  their receptors include
bronchoconstriction (Dahlén et al., 1980;    Davidson et  al., 1987),  attracting
eosinophils  and  neutrophils  (Laitinen et al., 1993),  induction  of  cytokine
expression (Mellor, E. A., Austen & Boyce, 2002;   Mellor, Elizabeth A. et al.,
2003), vascular leakage (Beller et al., 2004b), endothelial activation, dendritic cell
migration (Machida et al., 2004) and tissue repair (Peters-Golden et al., 2002;
Beller et al., 2004a).
Prostaglandins are produced through the activity of cyclooxygenase (COX) on
arachidonic acid. The major COX product in MCs after allergen induced activation
is PGD2 (Lewis et al., 1982), which exerts its effect through the receptors DP and
chemoattractant receptor-homologue molecule expressed on TH2  cells  (CRTH2)
(Narumiya, Sugimoto & Ushikubi, 1999;   Hirai et al., 2001). Mice lacking DP
have reduced TH2 cytokine production and reduced cellular infiltration in  an
allergen-induced asthma model, indicating a role for PGD2  and  its  receptors
(Matsuoka et al., 2000).
Cytokines
One way for MCs to influence their environment is through expression and release
of cytokines. Some cytokines are stored in the secretory granules, ready to be
released  upon  activation,  thereby  being  classified  as  one  of  the  preformed
mediators. One proinflammatory cytokine associated with MC granules is TNF-α
(Young et al., 1987;    Walsh et al., 1991), which is  a potent multi-functional
cytokine involved in leukocyte extravasation through up-regulation of endothelial
leukocyte adhesion molecule-1 (Messadi et al., 1987). TNF-α is also involved in
maturation and migration of dendritic cells (Cumberbatch, Fielding  &  Kimber,
1994) and the induction of  inflammatory mediator responses in  macrophages,
neutrophils and MCs (Sirois et al., 2000;  Coward et al., 2002). Apart from the
TNF-α already present in  granules,  additional  expression of  this  cytokine  is
accomplished  upon  MC  activation  via  several  of  the  previously  discussed
pathways, i.e. FcεRI, FcγRI, TLR, substance P (Gordon, J. R.  &  Galli,  1990;
Gordon, J. & Galli, 1991;   Cocchiara et  al., 1999;    Okayama, Yoshimichi,
Hagaman & Metcalfe, 2001;  Matsushima et al., 2004).
Other cytokines produced by MCs include IL-3, IL-4, IL-5, IL-6, IL-8, IL-10,
IL-13, GM-CSF bFGF-2 and TGF-β1 (Razin, Leslie & Schrader, 1991;  Okayama,
Y. et al., 1995a;  Okayama, Y. et al., 1995b;  Qu et al., 1998;  Ishizuka et al.,
1999a; b;  Kanbe et al., 1999;  Kobayashi, Ishizuka & Okayama, 2000). IL-3 is
important in MC development and is used to differentiate bone marrow cells into
functional MCs (Razin et al., 1984). IL-4, another TH2 cytokine, is  involved in
modulating MC responses through its regulation of receptor expression (FcεRI,16
kit) (Toru et al., 1996;   Mirmonsef et al., 1999), cysLT biosynthetic enzymes
(LTC4S) (Hsieh et al., 2001) and growth/survival (Growth arrest-specific protein-
1) (Lora et al., 2003). A subset of cytokines, the chemoattractant cytokines also
denoted chemokines, can also be expressed by  MCs.  The macrophage/monocyte
attracting chemokines RANTES and MCP-1  (Ono,  S.  J.  et  al.,  2003)  are
expressed by MCs as well as the neutrophil attracting IL-8 (Mukaida, Harada &
Matsushima, 1998;  Wakahara et al., 2001).
Preformed mediators
Histamine
Histamine was first found in 1910, and has since been regarded as one of the most
important  biogenic  amines.  It  is  produced  in  many  cell  types  through
decarboxylation of histidine, but the main sources of histamine are MCs (Riley &
West, 1952) and basophils (Ishizaka et al., 1972). Histamine is  associated with
smooth muscle contraction, increased vascular permeability, gastric acid secretion,
neurotransmission,  immunomodulation  and  proliferation.  It  exerts  its  effect
through interaction the histamine receptors H1,  H2,  H3,  H4,  which are G-protein
coupled receptors with wide and differential tissue distribution (Haaksma, Leurs &
Timmerman, 1990;  Hill, 1990). H1 is found on blood vessels, smooth muscles,
in heart and CNS, H2 is found in gastric mucosa, heart, uterus and CNS and H3 is
located in the airways, the GI tract and the CNS  (Bachert, 2002).   In allergic
diseases,  the  interaction  of  histamine  and  its  H1-receptor causes symptoms
associated  with  allergy,  including  vascular  permeability,  smooth  muscle
contraction and vasodilatation (Howarth, 1990;  White, 1990).  
In  addition  to  being  a  source  of  histamine,  MCs  also  express  histamine
receptors H1, H2 and H4 (Yanni et al., 1997;  Lippert et al., 2004), indicating an
autocrine/paracrine activation mechanism. In order to further clarify the biological
function of histamine, a mouse  strain  lacking  the  enzyme responsible for  its
biosynthesis, histidine decarboxylase (HDC), was developed. Deficiency in HDC
caused alterations in MC morphology and granule content; the knock-outs have
fewer MCs, and both the proteoglycan and protease amount in the MC  granules
are drastically decreased (Ohtsu et al., 2001). This strain has been used to show
the influence of histamine in contact dermatitis (Seike et al., 2005), gastric acid
secretion (Tanaka, S. et al., 2002) and angiogenesis (Ghosh et al., 2002).
Proteoglycans
Proteoglycans (PGs) are essential components of MC granules. They are made up
of a protein core with glycosaminoglycan (GAG) side chains. GAGs are long,
unbranched sugar chains with repeating disaccharide units attached to  the  core
protein via a linker consisting of a xylose followed by two galactose residues and
one glucuronic acid (GlcUA). There are many species of PGs,  defined both  by
their core protein as well as by their side chains. It is suggested that the major core
protein in MCs is serglycin (Stevens, Richard L. et al., 1988;    Kjellen et al.,
1989;  Åbrink, Grujic & Pejler, 2004), whilst its GAG chain differs in different
MC subtypes. Rodent connective tissue type MCs exclusively store PGs with17
heparin side chains (Yurt, Leid & Austen, 1977), whereas the MCs  of mucosal
subtype have PGs with chondroitin sulfate (CS) side chains  (Enerbäck et  al.,
1985). In contrast, human MCs contain both heparin and CS  regardless of MC
subtype (Stevens, R. L. et al., 1988).
The biosynthesis of GAG chains is intricate and several enzymes are involved in
the elongation and modification that takes place in the Golgi apparatus. Once the
linker region (Xylose-Galactose-Galactose-GlcUA) is attached to a serine residue in
the  core  protein,  the  chain  is  elongated  by  alternating  addition  of  N-
acetylgalactosamine (GalNAc) and GlcUA by chondroitin sulfate polymerase in the
case  of  CS.  Heparin  and  heparan  sulfate  chains  consist  of  alternating  N-
acetylglucosamine (GlcNAc) and GlcUA residues added by the enzymes EXT1 and
EXT2, which need to form heterodimers in order to reach maximal activity (Lind
et al., 1998;   Mccormick et al., 2000). Knock-out mice devoid of  EXT1  are
embryonic lethal and heterozygote individuals show diminished heparan sulfate
synthesis (Lin, X. et al., 2000). After EXT1/EXT2 have added the sugar residue,
sulfate groups are introduced at various positions.
Figure 2: Biosynthesis of heparin/heparan sulfate and chondroitin sulfate
The first modification in heparin synthesis is carried out  by  glucosaminyl N-
deactylase/N-sulfotransferases (NDSTs), which replaces the  acetyl group  in  N-
acetylglucosamine with a sulfate group. This alteration is essential for subsequent
modifications as they can only take place in the vicinity of N-sulfate groups. Four18
isoforms of NDSTs have been characterized in mouse; NDST-1  and  –2  are
ubiquitously expressed in embryonic and adult tissue,  but  at varying levels. In
contrast, NDST-3 and –4 are predominantly expressed  during  embryogenesis
although NDST-3 is also found in adult heart and brain (Humphries, Lanciotti &
Karlinsky,  1998;    Kusche-Gullberg et  al.,  1998;    Toma,  Berninsone  &
Hirschberg, 1998;  Aikawa & Esko, 1999;  Aikawa et al., 2001). Crystallization
of the sulfotransferase domain of NDST-1, and modeling of the other  three
isozymes based on the NDST-1 structure revealed differences in substrate binding
pockets, implying differences in  substrate specificity (Aikawa &  Esko,  1999;
Kakuta et al., 1999).  Biochemical studies  showed  that  NDST-2  was  able  to
generate longer GAG chains with higher N-sulfate content compared to  NDST-1
(Cheung et al., 1996;   Pikas,  Eriksson  &  Kjellen,  2000).  Mice  deficient in
NDST-2 had a less severe phenotype than expected, as the effect was restricted to
CTMCs despite its wide distribution. There are fewer MCs in this strain, and the
storage of neutral proteases and histamine is  impaired as a consequence of the
absence of heparin (Forsberg et al., 1999). Apparently, CTMCs are restricted to
express NDST-2, whereas the majority of cell types express at least two isozymes,
which would explain the  observed phenotype due  to  a  lack  of  compensatory
isozyme in CTMCs. Deficiency of NDST-1 causes embryonic or neonatal death
due to e.g. lung- and skull-defects (Fan et al., 2000;  Ringvall et al., 2000) and
analysis of organs revealed large reduction of heparan sulfate (HS) in  basement
membranes implying that NDST-1 has an important role in HS synthesis.
Further modifications of the sugar residues, after the step catalyzed by NDSTs,
involve conversion of GlcUA into iduronic acid (IdoUA), 2-O-sulfation of GlcUA
and IdoUA, as well as 6-O- and 3-O-sulfation of the aminosugar residues. Mice
strains unable to convert GlcUA to IdoUA  or  to  perform  2-O-sulfation  are
neonatally lethal following lung and kidney failure (Bullock et al., 1998;  Li et
al., 2003).
Proteases
Some of the major MC components expelled upon degranulation include proteases
that are active at neutral pH; as much as 35% of total protein content  in  the
granules is made up of these proteases (Schwartz et al., 1987a;  Schwartz et al.,
1987b). This group consists of e.g. tryptases, chymases and  carboxypeptidase,
which  are  stored  in  their  active  forms  in  the  granules  in  complex  with
proteoglycans (Forsberg et  al., 1999;    Åbrink,  Grujic  &  Pejler,  2004).  MC
granule proteases are synthesized as preproproteins, containing a hydrophobic
signal peptide and a 2 to 94 amino acid long propeptide. The signal peptide is
removed  in  the  endoplasmic  reticulum,  whereas the  location  for  propeptide
removal is yet to be elucidated.
Carboxypeptidase A
Carboxypeptidase  A  (CPA)  is  a  Zn
2+-dependent  exopeptidase  found  in
CTMC/MCTC subsets (Everitt & Neurath, 1980;  Goldstein, S.  M. et al., 1987;
Reynolds et al., 1989;  Irani et al., 1991). Activation of this protease is suggested19
to take place within the MC granules (Dikov et al., 1994;  Springman, Dikov &
Serafin, 1995) and cathepsin E is involved in this  process (Henningsson et al.,
2005). The mature CPA carries a high positive charge, and its positively charged
residues provide a means by  which it  may interact with  a PG,  to  which CPA
remains bound once exocytosed (Serafin et al., 1987;  Goldstein, S. et al., 1992).
The importance of proteoglycan binding is evident  in  mice  lacking  heparin
proteoglycan in MCs as a consequence of gene targeting of the enzyme NDST-2
(Forsberg et al., 1999), where the storage of several proteases is  impaired. The
activation of CPA seems to be dependent on the species of proteoglycan present in
MCs;  Henningsson  et al. showed that MCs lacking  heparin proteoglycan had
impaired CPA  activation and  that  chondroitin  sulfate proteoglycan could  not
substitute for heparin proteoglycan in this context (Henningsson et al., 2002).
Being a carboxy exopeptidase, CPA processes peptides from their C-terminal and
displays preferential proteolysis after aliphatic or aromatic amino acid  residues
(Everitt & Neurath, 1980;  Goldstein, S. M. et al., 1987).
The biological role of MC CPA has remained elusive, but it has been suggested
that CPA may act in concert with chymase since they are localized to  the same
macromolecular  proteoglycan  complex  (Goldstein,  S. et al.,  1992).  Further
support of this cooperativity was described in a study of MC involvement  in
processing of the vasoactive peptide, endothelin-1 (ET-1), where use of selective
inhibitors as well as purified components showed that CPA  and chymase could
indeed  cooperate in  the  processing  of  ET-1  (Metsarinne et al., 2002). More
evidence of the interdependence of CPA and chymase is displayed by CPA knock-
out mice, in which the lack of CPA also causes mMCP-5 deficiency  without
affecting the mRNA levels for this chymase (Feyerabend et al., 2005).
Matrix Metalloproteases
Matrix metalloproteases (MMPs) comprise a family of Zn
2+  and Ca
2+  dependent
metalloproteases with 25  members described in  vertebrates so  far (Nagase &
Woessner, 1999;   Lohi et al., 2001). These members can be divided into  eight
groups based  on  their  domains.  The  minimal  domain  MMPs  consist  of  the
common denominators for the family; a signal peptide, an inhibiting  propeptide
and a catalytic domain with a Zn
2+-binding site.  Members of this  subgroup are
matrilysin (MMP-7) and matrilysin-2 (MMP-26). A  structure common to  most
MMPs, except for minimal domain MMPs and MMP-23, is the hemopexin-like
domain, which connects to the catalytic domain through a linker region of variable
length.  The hemopexin domain is involved in protein-protein interactions, such
as substrate binding and binding of tissue inhibitors of metalloproteases (TIMPs).
Mutational studies show that the hemopexin domain in collagenase-1 (MMP-1) is
involved in local unwinding of the collagen triple helix, which enables proteolysis
of the individual collagen chains (Murphy et al., 1992;    Sanchez-Lopez et al.,
1993;   Overall, 2001).  The  linker  region,  although  it  is  absent  in  MMP-21
(XMMP), seems to be of importance in  autoactivation and substrate specificity
(Knauper et al., 1997). Although most MMPs are secreted, some remain bound to
the cell membrane, either through a transmembrane domain with a cytoplasmatic
tail  (MT-MMPs),  or  through  a  glycophosphatidyl  inositol  (GPI)  anchor.20
Members of the subgroup referred to as gelatinases (MMP-2 and MMP-9) have a
collagen binding domain made up of three fibronectin type II like repeats, which
facilitates interaction with collagenous substrates and elastin (Steffensen, Wallon
& Overall, 1995), fatty acids (Berton et al., 2001) and thrombospondins (Bein &
Simons, 2000).
Figure 3: Schematic view of MMP composition21
There are several levels of regulation of MMP activity, including transcription,
secretion, enzyme activation and inhibition. Most MMPs, with the exception of
the constitutively expressed MMP-2 (Fini & Girard, 1990;    Birkedal-Hansen et
al.,  1993),  are  regulated  at  the  transcriptional level.  Factors  that  influence
transcription include phorbol esters (Mackay et al., 1992), integrin-derived signals
(Wize et al., 1998;  Xie, Laouar & Huberman, 1998), cell stress, changes in cell
shape (Kheradmand et al., 1998;  Tyagi et al., 1998) and cytokines (Ogata et al.,
1992). The mediators for several of these inducers are activator protein-1 sites
within the MMP gene promotor-regions (Lin, C. W., Georgescu & Evans, 1993).
Stability of the mRNA also affects expression of MMPs.  Phorbol esters can
increase the stability  of  transcripts of  MMP-1  and  MMP-3,  whereas TGF-β1
destabilizes mRNA for e.g. MMP-13 (Delany et al., 1995;  Vincenti, 2001;  Iyer,
Pumiglia & Dipersio, 2005). Most MMPs are secreted once translated, but some,
such as MMP-8  in  neutrophils and MMP-9  in  differentiating granulocytes, are
retained in granules until the cells become activated (Christner et al., 1982;  Hibbs
& Bainton, 1989;  Borregaard et al., 1995).
Like most proteolytic enzymes, MMPs  translate into zymogens, and  their
latency depends on the interaction between a cysteine in  the propeptide and the
active site Zn
2+-ion. This interaction can be disrupted through proteolysis of the
propeptide, or through the action of reactive oxygen species (Rajagopalan et al.,
1996;   Owens et al., 1997;    Meli,  Christen &  Leib,  2003). Many MMPs  are
secreted as zymogens, but some that contain a furin-like enzyme recognition motif
can be activated before secretion.  Extracellular activation can be accomplished by
already activated MMPs as well as by  several different serine proteases.   An
interesting activation mechanism is described for MMP-2; a TIMP-2 complexed
with MT1-MMP binds the  hemopexin domain  of  proMMP-2,  which  is  then
activated by an adjacent MT1-MMP (Deryugina et al., 2001).
Besides general protease inhibitors such as α2-macroglobulin, there is a group of
reversible inhibitors with higher specificity towards different MMPs. This group
of tissue inhibitors of metalloproteases has four members (TIMP-1, -2,  -3,  -4),
which inhibit MMPs through interaction of the TIMP N-terminus with the active
site of MMP (Gomis-Ruth et al., 1997).
Initially, MMPs were recognized for their ability to degrade the components of
the extracellular matrix. It is now established that these enzymes have several non-
matrix proteins as substrates, including  cytokines,  chemokines, inhibitors  and
receptors (Sternlicht & Werb, 2001;   Folgueras et al., 2004).   MCs can be a
source of certain MMPs.  Mouse MCs  express MMP-9  as progenitors and this
synthesis is down-regulated by SCF (Tanaka, A. et al., 1999). Expression of this
MMP is also described in dog (Fang et al., 1996) and human MCs (Kanbe, N. et
al., 1999), but in contrast to the murine system,  the expression is  up-regulated
upon c-kit stimulation (Fang et al., 1999). Addition of TGF-β1  to  dog  MCs
abolishes expression of MMP-9, and decreases the SCF-induced expression. MCs
have an autocrine regulation of MMP-9 expression; TNF-α released upon MC
stimulation activates T-cells, and the activated T-cells stimulate MCs to  express22
MMP-9 through interaction of LFA -1 and ICAM-1 (Baram et al., 2001;  Brill et
al., 2004). MC expression of MMP-9 is also affected by direct stimulation, e.g.
through FCεRI (Tanaka, A. & Matsuda, 2004) and TLRs (Tanaka, A., Yamane &
Matsuda, 2001;  Ikeda & Funaba, 2003). Expression of the collagenase MMP-1 is
also detected in human MCs (Di Girolamo & Wakefield, 2000;  Edwards et al.,
2005).
Tryptase
Tryptases are serine proteases with trypsin-like substrate specificity, i.e. cleavage
after basic amino acids. Human MCs have two major tryptase groups; α-tryptases
consisting of αI and αII subtypes (Miller, Westin & Schwartz, 1989;  Pallaoro et
al., 1999) and β-tryptases with βI, βII and  βIII subtypes  (Miller,  Moxley  &
Schwartz, 1990;  Vanderslice et al., 1990). Precursors of α- and β-tryptases are
secreted constitutively, but α-tryptase is the predominant form detected in serum
under normal conditions (Schwartz et al., 1995;  Schwartz et al., 2003). Active β-
tryptases, however, are retained in the MC granules. Furthermore, α-tryptase has
much lower activity than β-tryptase due to an amino acid substitution in the active
site as well as structural differences in the substrate binding domain (Huang et al.,
1999;  Marquardt et al., 2002). There appears to be a redundancy of α-tryptases,
with as much as 29% of the population lacking this  subtype with  no  apparent
clinical effects (Soto et al., 2002). Additional members of this  serine protease
family include the δ-tryptases (δI and δII) (Wang et al., 2002) and the membrane-
associated  γ-tryptases  (γI and γII)  (Caughey et al., 2000). Tryptases so  far
described in murine MCs include  mMCP-6,  mMCP-7,  mouse  transmembrane
tryptase (mTMT) and mMCP-11. The mouse tryptase most similar to human β-
tryptase is mMCP-6,  both  in  amino acid composition and substrate specificity
(Huang,  C. et al., 2001). Expression of  tryptases differs between human  and
rodents in that  all  human  MCs  contain  tryptase,  whereas tryptase storage in
murine MCs seems to be restricted to CTMCs.
Activation of tryptase may be accomplished in two steps, where the first step is
an  autocatalytic  cleavage.  The  second  step,  which  might  involve
dipeptidylpeptidase (DPPI), removes the remaining dipeptide to form the mature
monomers (Sakai, Ren & Schwartz, 1996;  Wolters et al., 2001). Active tryptase
is stored in MC granules in a tetrameric structure in complex with heparin, with
the active sites of the monomers facing a central pore (Schwartz, Lewis & Austen,
1981;   Schwartz & Bradford, 1986;   Pereira et al., 1998). The assembly  and
stabilization of the tetramers is dependent on acidic pH, since the interaction of
heparin and tryptase is mediated by histidines that become uncharged at neutral
pH, thereby disrupting the ionic interaction (Hallgren et al., 2000;   Hallgren,
Spillmann & Pejler, 2001;   Hallgren et al., 2004;  Hallgren, Lindahl &  Pejler,
2005). Because of the organization of the tetramer, macromolecular active site
inhibitors and large substrates are excluded from the active sites, giving tryptase
its specificity towards substrates that are small enough to enter the central pore.
Tryptase is suggested to have anticoagulant activity,  since  it  can  degrade
fibrinogen,  thereby  limiting  blood  clot  formation  (Schwartz et al.,  1985).23
Increased vascular permeability through activation of prekallikrin and production
of bradykinin from kininogen is also attributed to  tryptase activity (Imamura et
al.,  1996;    Kozik et  al.,  1998).  Tryptase  may  induce  increased bronchial
responsiveness due to degradation of bronchiodilating neuropeptides such as VIP,
peptide histidine-methionine and (Walls et al., 1992) calcitonine gene-related
peptide (Caughey et al., 1988;   Tam &  Caughey, 1990;    Walls et al., 1992).
Degradation of these neuropeptides is associated with  asthma, and tryptase may
further contribute to this condition by causing thickening of airway walls through
increased proliferation of fibroblasts, smooth  muscle  cells  and  epithelial  cells
(Ruoss, Hartmann & Caughey,  1991;    Brown et  al., 1995).  It  was  recently
discovered that active tryptase monomers can be formed and that these monomers
are able to process fibronectin, a protein otherwise excluded from the  tetramer
active  site  (Hallgren,  Spillmann  &  Pejler,  2001;   Fajardo  &  Pejler,  2003).
However, the existence of active tryptase monomers in vivo remains to be proven.
Cathepsin G
Human MCTCs express Cathepsin G, which is a serine protease that  has  both
tryptic and chymotryptic substrate specificity (Schechter et al., 1990). Its presence
in rodent MCs requires further investigation,  since  contradictory results  exist.
Spleen-derived mouse MCs contain transcripts for Cathepsin G,  while CTMCs
collected from rat peritoneum do not (Lutzelschwab et al., 1997;    Jippo et al.,
1999).
Chymase
This family of serine proteases with  chymotrypsin-like substrate specificity was
first described in 1959 (Benditt & Arase, 1959). Chymases preferentially cleave
substrates  at  sites  following  aromatic  residues,  in  a  manner  similar  to
chymotrypsin (Powers et al., 1985). MCs store active chymases in their granules,
but synthesize them as inactive precursors. The zymogen has an acidic dipeptide
that is removed by DPPI (Wolters et al., 2001). Removal of the propeptide causes
a conformational  change  in  the  chymase  that  results  in  an  active  protease
(Murakami, Karnik & Husain, 1995).
Classically, the chymases are divided into  two  groups based on  phylogenetic
analysis  and  the  proteolysis  pattern  of  the  peptide  angiotensin  I  (AngI)
(Chandrasekharan et al., 1996). Chymases that preferentially produce angiotensin
II (AngII) by cleaving the Phe
8-His
9-bond are classified as α-chymases, whereas
those that degrade AngI by proteolysis of the Tyr
4-Ile
5 bond belong to the  β-
chymase family. Only one chymase-expressing gene is identified in humans and it
translates into an α-chymase (Caughey, Zerweck &  Vanderslice, 1991), whereas
rodents express a  number  of  chymases.  Mouse  mucosal  MCs  express the  β-
chymases mMCP-1, mMCP-2 and mMCP-9 whereas the CTMCs contain the β-
chymase mMCP-4 and the α-chymase mMCP-5.    The functional classification
regarding angiotensin  I  processing  has  been  re-evaluated as  the  β-chymases
mMCP-1 and mMCP-4, as well as dog α-chymase, cleaves at both Tyr
4-Ile
5 and
Phe
8-His
9 (Caughey, Raymond & Wolters, 2000;  Saito et al., 2003).  Mutational
studies  of  human  α-chymase  revealed  that  Gly
216  is  responsible  for  its24
chymotrypsin-like  specificity,  since  substitution  of  this  residue  into  valine
switched the  specificity  to  one  resembling  elastase  (Solivan et  al.,  2002).
Interestingly,  rodent  α-chymases have Val instead of   Gly in that position,
implying that they are elastase-like proteases, a notion confirmed by phage-display
analysis (Kunori et al., 2002;  Karlson et al., 2003).
There are a number of ways to regulate the  biological  activity  of  chymase.
Several  endogenous  inhibitors,  such  as  α1-antichymotrypsin  and  α2-
macroglobulin, can interact with the protease, thereby limiting the  chymase-
associated proteolysis (Fukusen et al., 1987;  Schechter et al., 1989).  Chymase is
stored in complex with proteoglycans and some  remain attached to  the  GAG
chains after degranulation. This interaction makes chymase less  susceptible to
inhibition by the large macro-molecular inhibitors mentioned, but  it  does  not
protect  against  low  molecular  weight  inhibitors  such  as  chymostatin  and
phenylmethanesulfonyl fluoride (Pejler & Berg, 1995;    Lindstedt,  L.,  Lee  &
Kovanen, 2001). The proteoglycan can also act  as  a  scaffold  that  mediates
interaction  between  chymase  and  its  substrates.  This  could  be  through
neutralization of positive charges on chymase and substrate that would otherwise
disturb their interaction, as demonstrated using a charged chromogenic substrate
(Pejler  &  Sadler,  1999).  The  proteoglycan  can  also  increase  the  substrate
availability by sequestering it from the solution and presenting it to the protease
(Pejler & Sadler, 1999;  Tchougounova & Pejler, 2001).
In vitro studies have implicated chymase in processing a wide array of proteins.
Human chymase can activate the  highly  potent  inflammatory cytokine,  IL-1β
(Mizutani et al., 1991), release cell-associated SCF  and latent TGF-β1 (Taipale et
al., 1995;  De Paulis et al., 1999) and degrade albumin (Raymond et al., 2003).
In a physiological context, chymase might be associated with  tissue remodeling
through  activation  of  TGF-β1,  proMMP-1,  proMMP-3,  proMMP-9  and
degradation of fibronectin and TIMPs (Vartio, Seppa & Vaheri, 1981;  Saarinen et
al., 1994;  Suzuki et al., 1995;  Fang et al., 1996;  Fang et al., 1997;  Frank et
al., 2001;  Lindstedt, K. A. et al., 2001;  Leskinen et al., 2003;  Okumura, K. et
al., 2004). Additional evidence for chymase being involved in tissue regulation is
displayed in a model of fibrosis, where chymase inhibitors reduced the fibrotic
response towards bleomycin (Tomimori et al., 2003;  Sakaguchi et al., 2004). In
addition, the development of fibrosis is accompanied by increased  levels  of
chymase in a model of scleroderma, and the development is ameliorated by  a
chymase inhibitor (Kakizoe et al., 2001;  Shiota et al., 2005).
A possible role in coagulation is proposed as chymase can degrade thrombin and
plasmin (Pejler & Karlström, 1993;  Tchougounova & Pejler, 2001). Furthermore,
chymase may contribute to the pathology of e.g. atopic and chronic dermatitis as
illustrated in studies where injection of chymase provoked similar symptoms  to
those experienced in these conditions (Tomimori et al., 2002;  Watanabe et al.,
2002).  The  injections  induced  eosinophil  and  neutrophil  influx  following
increased vascular permeability (He & Walls, 1998a; b).25
To further elucidate chymase’s in vivo role, transgenic mice lacking individual
chymases have been developed. Targeted disruption  of  the  gene  encoding the
MMC β-chymase mMCP-1 showed for the first time that chymase is involved in
defense against parasites. This chymase is found in the circulation, and its level is
increased upon infection with e.g. Trichinella spiralis, peaking as the parasite is
expulsed (Huntley et al., 1990). A strain deficient in mMCP-1 displays delayed
remission and increased larvae depositions when infected with T. spiralis (Knight
et  al., 2000).   A strain that  lacks  the  α-chymase mMCP-5  exists  and  these
animals have less severe muscle injuries following ischemia-reperfusion (Abonia et
al., 2005). However, the results obtained using this strain are compromised
because the mMCP-5 deficiency causes a lack of CPA.  The β-chymase mMCP-4
is the major chymotryptic protease present in skin, as deduced from analysis of a
strain  that  is  devoid  of  this  protease.  This  strain  also  exhibits  impaired
fibronectin, plasmin and thrombin degradation, supporting the in  vitro findings
(Tchougounova, Pejler & Åbrink, 2003).
The mast cell in its physiological context
The tissue distribution of MCs in the gastrointestinal  tract,  skin  and  airways
suggests  a  role  in  defense  against  invading  pathogens.  Helminths,  such  as
nematodes and schistosomes, induce a TH2 response, which involves secretion of
IL-4, IL-5, IL-6, IL-10 and IL-13 followed by eosinophilia, mastocytosis and IgE
production (Madden et al., 1991;  Finkelman et al., 1997;  Maizels & Holland,
1998). Signaling through the IL-4 receptor (IL-4R)  seems  to  be  important  in
nematode clearance, since blocking antibodies against IL-4Rα abrogate expulsion
of Nippostronglyus brasiliensis (Urban et al., 1998). Studies using MC-deficient
mice (W/W
v)  show  that  MCs  are  important,  but  not  essential,  for  parasite
clearance, since the recovery of MC-deficient mice infected with  Stronglyoides
venezuelensis or Trichinella spiralis is delayed compared to normal mice (Ha,
Reed & Crowle, 1983;  Lantz et al., 1998). Different MC mediators contribute to
elimination of different nematodes. The β-chymase mMCP-1  is  involved  in
expulsion of T. spiralis but does not affect clearance of N. brasiliensis (Knight et
al., 2000). Additional investigations of mMCP-1
-/- mice reveal that neutrophil
infiltration and TNF-α levels are decreased compared to wild type mice after T.
spiralis infection (Lawrence, C. E. et al., 2004).  
As previously discussed, MCs express TLRs that recognize bacterial and viral
components. In addition to releasing mediators following recognition, the MCs
can phagocytose bacteria and function as antigen-presenting cells (Banovac et al.,
1989;  Malaviya et al., 1994;  Frandji et al., 1995;  Arock et al., 1998;  Tkaczyk
et al., 1999). In contrast to normal mice, MC-deficient mice  show  a  reduced
ability to fight bacterial infections and, highlighting the significance of MCs  in
host defense against these pathogens (Echtenacher, Mannel & Hultner, 1996). The
protection may be conferred through release of e.g. TNF-α, tryptase, LTC4, MIP-
1α, MIP-1β, MCP-1 and IL-8 (Malaviya et al., 1996;  Maurer, M. et al., 1998;26
Malaviya & Abraham, 2000;  Huang, Chifu et al., 2001;  Krishnaswamy et al.,
2001).
In some ways, the protective mediators can be used against the host  by  the
bacteria. An example of this is Shigella dysenteriae, which secretes shiga toxin
and triggers excessive release of LTC4, causing the diarrhea associated with  this
pathogen (Cruz et al., 1995;  Pulimood, Mathan & Mathan, 1998). Yet another
bacteria-associated pathology, where MCs  might  be the culprit, is  Helicobacter
pylori-induced gastritis. There is  an  increase of  MC  numbers  in  the  mucosa
following H. pylori infection and some products from this bacteria can cause MCs
to degranulate, thereby inducing a sustained inflammatory process (Plebani et al.,
1994;  Nakajima et al., 1997;  Yamamoto et al., 1999).
The immune system is designed to be protective against harmful entities, but
sometimes it reacts towards seemingly harmless matter and manifests itself e.g. as
allergies and allergic asthma.  MCs play a major role in the early phase of allergic
inflammation,  which  is  clearly  demonstrated  in  a  model  for  type  I
hypersensitivity, passive cutaneous anaphylaxis (PCA). It is not possible to detect
a PCA reaction in mice devoid of MCs (W/W
v), whereas reconstitution with MCs
restores the anaphylaxis (Wershil et al., 1987).
Functional studies have revealed that MCs are involved in several pathological
conditions. One group of diseases is the autoimmune disorders, such as multiple
sclerosis (MS) and rheumatoid  arthritis  (RA).  Gene-array experiments  reveal
evidence for MC involvement in MS progression; the number of MC-derived or
MC-associated transcripts increases in sclerotic brain lesions (Lock et al., 2002).
Furthermore,  in  a  mouse  model  for  MS,  experimental  autoimmune
encephalomyelitis (EAE), the absence of MCs resulted in a delayed onset of the
disease and also a decreased severity of the symptoms (Secor et al., 2000).  
The influence of MC on arthritic development is even more dramatic.  Mice
devoid of MC (W/W
v and Sl/Sl
d) do not develop antibody-induced arthritis (Lee,
D. M. et al., 2002). Moreover, MC degranulation exclusively in the joints is the
first detectable reaction after administration of arthritogenic antibodies to wild type
and MC-reconstituted mice. Other arthritis models substantiate these results, e.g.
in collagen-induced arthritis where MCs accumulate and degranulate in the paws of
affected animals (Malfait et al., 1999).
MCs are also associated with cancer and they often accumulate in the vicinity of
tumors. It is likely that MCs contribute to the growth and progression of tumors,
as  the  MCs  are  rich  sources  of  growth  factors  and  angiogenic  cytokines.
Additionally, there is a correlation between MC numbers and a poor prognosis in
e.g. Hodgkin’s lymphoma (Molin et al., 2002).27
Present investigations
Aim
The purpose of the present investigations is to elucidate the functional aspects of
MC proteases and to understand how proteoglycans regulate their  activity  and
storage.
Results and discussion
Paper I: Polycationic peptides as inhibitors of mast cell serine
proteases.
Heparin affects the activity of chymase towards certain substrates as well as its
susceptibility to endogenous inhibitors. Furthermore,  the  interaction  between
tryptase and heparin proteoglycan is essential for proper assembly and activation of
this tetrameric serine protease, and the association with heparin stabilizes tryptase
tetramers.  Additional  interactions  that  stabilize  tryptase  tetramers  include
hydrophobic and ionic interactions. We thus  examined whether repeats of  the
heparin-binding  motifs,  XBBXBX  and  XBBBXXBX  (X;  hydrophobic  or
uncharged, B; basic amino-acid), and homopolymers of arginine and lysine have
the ability to inhibit tryptase and chymase activity.
Inhibitory studies revealed that the peptides constructed from heparin-binding
motifs are inefficient inhibitors of heparin-free  human  βI-tryptase, but  show
potency towards the chymase, rMCP-1. Polymers of lysine and arginine are potent
inhibitors of both tryptase and chymase, with IC50-values in the nanomolar range.
The homopolymers are competitive inhibitors of chymase and since the polymers
have very little inhibitory effect on  heparin-free chymase, it  is  likely that they
inhibit this protease by  displacing it  from heparin. Previous studies show that
thrombin is inactivated by chymase released from rodent peritoneal cells, and that
this process is  largely heparin-dependent (Pejler &  Karlström,  1993;    Pejler,
Söderström & Karlström, 1994;  Tchougounova & Pejler, 2001). To  assess the
efficacy of the  polycations  in  a  setting  more  closely  resembling the  in  vivo
situation, we tested if  they could inhibit  thrombin inactivation in  this  cellular
system. Both poly-Lys and poly-Arg could inhibit the proteolysis of thrombin at
nM concentrations, but polymers of the heparin-binding motifs had no effect.
Poly-Lys and poly-Arg display differential inhibitory modes of action regarding
tryptase; poly-Arg appears to be a strict competitive inhibitor of tryptase, whilst
poly-Lys acts with mixed competitive and non-competitive inhibition kinetics.
Because the tryptase preparation used in  this  study  was devoid of heparin, the
inhibitors must  interact directly with  the protease. Moreover, we addressed the
issue of whether polycationic inhibition of tryptase is reversible, and if  the
interaction between enzyme and inhibitor causes a conformational alteration in the
tetramer. Addition of an excess of heparin to the enzyme-inhibitor  mix  partly
restored the activity that was lost due to the inhibitors, but this ability decreased
over  time.  A  prominent  trait  of  the  tryptase  tetramer  is  its  resilience  to28
macromolecular  inhibitors  (Pereira et al., 1998;   Sommerhoff et al., 1999),  a
feature we explored, to see if  the rescued tetramer had an altered conformation.
Addition of bovine pancreatic trypsin inhibitor (BPTI) does not affect naïve
tryptase, but had an impact  when  added to  polycation-treated, heparin-rescued
tryptase. The latter finding indicates that the polycationic  substances induce  a
rearrangement in the tetramer, making it more open and thereby more susceptible
to inhibitors.
The  results  in  this  study  suggest  that  polycationic  compounds  can  be  of
therapeutic interest when treating pathologies associated with MC serine proteases.
A possible limitation for their use is  their size, which probably prevents them
from exerting their  effects on  the  intended  pathways i.e. they  remain in  the
circulation  if  injected  intravenously.  However,  administration  of  the
macromolecular inhibitor lactoferrin successfully prevents bronchoconstriction in
allergic sheep (Elrod et al., 1997), which indicates that it is possible to use high
molecular weight substances in therapeutic intervention.
Paper II: Cooperation between Mast Cell Carboxypeptidase A and  the
Chymase  Mouse  Mast  Cell  Protease  4  in  the  Formation  and
Degradation of Angiotensin II.
MCs  are  associated  with  angiogenesis  and  cardiovascular  diseases,  but  the
components that influence these processes remain unclear. One bioactive peptide
that may mediate some of the ascribed features is the octapeptide, angiotensin II
(AngII), derived from  the  decapeptide, angiotensin  I  (AngI). Several in  vitro
studies show that MC chymase can produce AngII, and there are some in vivo data
implicating chymase in this process (Takai et al., 1999;  Caughey, Raymond &
Wolters, 2000;   Muramatsu et al., 2000). To determine the involvement of MC
proteases in the generation of AngII from AngI, we utilized a mouse strain that
lacks an enzyme essential for heparin proteoglycan biosynthesis, NDST-2. The
loss of the enzyme causes a granular storage defect, rendering the CTMCs virtually
devoid of neutral serine proteases. We also used a strain lacking the chymase,
mMCP-4, to define its contribution to the AngII formation.
We employed an ex vivo system, where AngI is added to peritoneal cells from
wild type and knock-out mice, and the conditioned media was analyzed for
presence of AngI-derived products. Initial studies using ELISA-based detection of
AngII revealed that degranulation of MC  drastically increased AngII formation.
Comparison of wild type and NDST-2
-/- cell cultures showed that the reduction in
proteases in the heparin-deficient cells caused an impaired ability to generate AngII
from AngI, a result corroborated by high perfomance  liquid  chromatography
(HPLC)-analysis of the conditioned media. HPLC analysis gave further insights
into the generation of other angiotensin-related peptides. Besides AngII, Ang(1-9),
Ang(1-7) and Ang(5-10) could be detected and quantified, and their formation was
also influenced to the same extent as AngII following degranulation. Inhibition of
chymotrypsin-like activity and removal of mMCP-4 did not affect the rate of AngI
proteolysis. It did, however, influence the levels of peptides derived from AngI, as
all peptides except Ang(5-10), which could not be detected, reached higher levels
in mMCP-4
-/- cultures compared to wild type.29
Additional inhibitory studies showed that a carboxypeptidase A inhibitor (CPI)
decreased the rate of AngI processing in wild type cultures. This effect was more
pronounced when combined with mMCP-4 deficiency, where AngI processing was
drastically decreased and formation of AngII essentially blocked. Addition of CPI
to wild type  or mMCP-4
-/-  cell cultures completely prevented the formation of
Ang(1-9) and Ang(1-7), which clearly showed that these bioactive peptides were
generated by CPA or a carboxypeptidase-like enzyme. In a physiological context,
this implies a regulatory, homeostatic role for MCs, where the MC proteases,
CPA and chymase, generate the vasoconstrictor, AngII, but  limit  its  effects by
producing its antagonists, Ang(1-9) and Ang(1-7).  Furthermore, it  may  be  of
clinical interest to inhibit both chymase and CPA, or selectively inhibit either of
them, e.g. following ischemia to limit the adverse effects of angiotensin-derived
peptides.
Paper III: A Key Role for Mast Cell Chymase in the Activation of Pro-
matrix Metalloprotease-9 and Pro-matrix Metalloprotease-2
In this paper, we explore how MCs participate in the regulation of the extracellular
matrix (ECM). Previous studies show that chymase can act directly on ECM-
components, such as fibronectin (Tchougounova et al., 2000;   Tchougounova,
Pejler & Åbrink, 2003). Furthermore, in vitro studies revealed that chymase can
activate proMMP-9 (Fang et al., 1996), an enzyme capable of degrading parts of
the ECM as well as activating growth factors that influence the synthesis of ECM-
components. MMP-9 belongs to a family comprised of 25 known members with
the common feature that they are all  metalloproteases synthesized as zymogens,
which require proteolytic processing to become active. Gelatinases, the sub-group
to which MMP-9 belongs, has another member called MMP-2 that is associated
with  tumor  progression  and  angiogenesis  (Itoh et al., 1998),  processes  also
associated with MCs.
We investigated the relevance  of  MC-dependent  activation  of  MMP-9  by
culturing mouse peritoneal cells, in either the presence or absence of MCs. In the
absence of MCs, endogenous proMMP-9 was not activated, whereas addition of
MCs increased the level of active MMP-9 in a dose-dependent manner.  We used
the heparin-deficient mouse strain, NDST-2
-/-,  to  elucidate the  involvement  of
heparin-dependent MC proteases in the generation of active MMP-9. Zymographic
analysis did not reveal any active MMP-9 in  NDST-2
-/-  peritoneal cell cultures,
thus implying a role for MC proteases in the proteolytic activation of proMMP-9.
Analysis of peritoneal cell cultures lacking the chymase, mMCP-4,  showed that
proMMP-9 accumulated in these cultures, while  active  MMP-9  was  absent,
indicating that mMCP-4 is involved in MMP-9 formation. This result  gained
additional support upon  analysis  of  tissue  homogenates, where the  deficit  in
mMCP-4 caused a complete abolition of active MMP-9  in  the studied tissues,
whilst homogenates of tissues from wild type mice contained both proMMP-9 and
its  active  form.  Further  comparison  of  wild  type  and  mMCP-4
-/-  tissue
homogenates suggested that  chymase might  activate proMMP-2,  as  mMCP-4
deficiency caused a partial reduction in active MMP-2 levels.30
To substantiate the discoveries, we carried out in situ zymographies on selected
tissues. This analysis revealed a strong reduction in gelatinolytic activities in the
dermal region of the ear, as well as in the surroundings of blood vessels and
bronchioli of the lungs, in mMCP-4
-/- compared to wild type. Histochemical and
amino acid analysis was carried out to investigate whether the reduction in MMP-
activity and lack  of  mMCP-4  caused alterations in  ECM-composition.  These
studies showed increased collagen-deposition in  mMCP-4
-/--skin.  Moreover, the
intensity following immunohistochemical detection of fibronectin was higher in
lungs and ears from mMCP-4-knock out mice,  implying  increased fibronectin
levels in these animals.
Taken  together,  the  results  presented  in  this  study  show  that  chymase
contributes to the formation of active MMP-2 and MMP-9,  and may be a key-
player in this process. Furthermore, we suggest that chymase influences tissue
homeostasis, partly through activation of MMPs and partly by acting on the ECM
directly. The present study thus clearly establishes a potential link  between MC
proteases and the development of pathologies associated with  changes in  ECM,
e.g. rheumatoid arthritis.
Paper IV: Mast Cell-dependent Activation of Pro-matrix
Metalloprotease-2: A Role for Serglycin Proteoglycan-dependent Mast
Cell Proteases.
In paper III, we detected a decreased activation of MMP-2 in tissues collected from
mice lacking the chymase, mMCP-4. We conducted this study to determine if this
chymase, or another MC protease, directly acts on proMMP-2 to generate active
MMP-2.
The rate of MMP-2 formation from exogenously added proMMP-2 increased in
peritoneal cell cultures after induction of MC  degranulation, which indicated an
involvement of MC proteases in proMMP-2 activation. In agreement with  the
degranulation study, elimination of MCs  from peritoneal cell cultures caused a
decreased formation of active MMP-2, but addition of MCs restored proMMP-2
activation. The MC-dependent proMMP-2 activation was susceptible to inhibitors
of serine proteases, but not to inhibitors of other enzyme-classes. It appears that
mMCP-4 was not the  major  proMMP-2  activator, as  MMP-2  formation was
similar in cultures lacking this chymase. However, the activation involved a MC
protease requiring the proteoglycan, serglycin, for its  storage, as determined by
analysis of cultures of serglycin-deficient peritoneal cells.
The results in this paper indicate that an MC serine protease, dependent  on
serglycin proteoglycan for its storage, can generate active MMP-2. This provides
an alternative route to the commonly  proposed mechanism,  which  involves  a
ternary complex between proMMP-2, TIMP-2 and MMP-14.31
Concluding remarks and future perspectives
MCs are intricate entities,  capable  of  providing  excellent  protection  against
invading pathogens, but also capable of causing serious harm to their host. Owing
to their wide array of mediators, they can influence the progression of  several
pathologies with which they are associated. Depending on the stimuli,  their effect
can be detrimental or beneficial. The  present  investigations  reveal  that  MC
proteases influence the integrity of the surrounding ECM, and that some of this
effect is mediated through activation of matrix degrading enzymes. However, MC
are implicated in both excessive ECM break-down as well  as  excessive ECM
deposition,  and  the  different  pathways  which  are  affected  need  further
investigation. In order to understand the mechanisms behind these  opposing
effects, identification of the affected mediators in each process is needed. One tool
for this identification is  proteomics,  which  enables simultaneous  detection of
proteins affected by a certain process. The use of this tool may reveal novel targets
for MC proteases and other MC components, and hence explanations for how MC
participate in different physiological conditions.
In addition to analysis of MC proteins,  it  is  of  interest  to  investigate the
composition  of  the  proteoglycans,  and  especially  their  GAG-chains.  The
characterization of sugars, referred to as glycomics, has attained increased attention
as mounting evidence show that the modifications of the sugar residues, and the
composition of polysaccharides, generate sequences that regulate protein- and cell-
interactions. An example of this is a penta-saccharide sequence in heparin, which
is required for  the  inhibition  of  thrombin  by  anti-thrombin.  Interaction-based
technology, e.g. surface plasmon  resonance and  affinity  chromatography, may
reveal additional sequences required for specific interactions and thereby provide
explanations for the involvement of MCs in different processes.
The construction of gene targeted mice, and the use of MC “knock-ins” are of
great interest for unveiling the physiological effects of MCs.  In depth analysis,
using e.g. proteomics and glycomics, to elucidate what the gene-deficiency affects
in various disease models will hopefully suggest what mediators  should  be
targeted in each disease.
An  intriguing  prospect  would  be  to  govern  the  MC  response  in  different
pathologies, making use of its  beneficial effects and minimizing  its  deleterious
potential. For example, it would be very useful if the angiogenic-related mediators
could be blocked, whilst not compromising the mediators capable of inducing
apoptosis when treating tumors. Based on indications from the studies conducted
in this thesis, inhibitors of chymase and CPA could be of therapeutic interest.32
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